News: Umeå, 9 August 2022.  Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming conferences.

LSX Nordic (https://www.lsxleaders.com/lsx-nordic-congress), Copenhagen, Denmark, 6-7 September             

Biostock Investerarevent, (https://www.biostock.se/2022/02/biostock-investor-meeting-14-september/) digital, 14 September

Nordic Life Science Days, (https://www.nlsdays.com/) Malmö, Sweden, 28-29 September

Bio-Europe, (https://informaconnect.com/bioeurope/?utm_source=iito.de&utm_medium=referral&utm_campaign=EBEU2020ViitoB&utm_term=GeneralBanners&utm_content=EBEU2020ViitoB&tracker_id=EBEU2020ViitoB) Leipzig, Germany, 24-26 October

Redeye Life Science Day (https://www.redeye.se/company/lipum?searchResult=028bb6d5-cc54-3998-aae5-945113c4cb2b&query=lipum&fromPage=FULL), Stockholm, Sweden, 24 November

Biostock Life Science Summit (https://www.biostock.se/en/2022/01/biostock-life-science-summit-2022/), Lund, Sweden, 29-30 November

"I am looking forward to these events. We are approaching clinical trials of our biological lead candidate SOL-116 and industry meetings provide good opportunities to present our progress", says CEO Einar Pontén.

For further information, please contact:
Einar Pontén, CEO
E-post:    einar.ponten@lipum.se
Mobil:     +46 70 578 34 95
Web:       www.lipum.se

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se,phone: +46 8 503 000 50.